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Summary
Pooling biomarker data across multiple studies allows for examination of a wider exposure range
than generally possible in individual studies, evaluation of population subgroups and disease sub-
types with more statistical power, and more precise estimation of biomarker-disease associations.
However, biomarker measurements often require calibration to a reference assay prior to pooling due
to assay and laboratory variability across studies. We propose several methods for calibrating and
combining biomarker data from nested case-control studies when reference assay data are obtained
from a subset of controls in each contributing study. Specifically, we describe a two-stage method
and two aggregated methods, named the internalized and full calibration methods, to evaluate the
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2 Sloan and Wang
main effect of the biomarker exposure on disease risk and whether that association is modified by
a potential covariate. The internalized method uses the reference laboratory measurement in the
analysis when available and otherwise uses the calibrated measurement. The full calibration method
uses calibrated biomarker measurements for all subjects, even those with reference laboratory mea-
surements. Our results demonstrate that the full calibration method is the preferred aggregated
approach to minimize bias in point estimates regardless of the inclusion of an interaction term in
the model. We also observe that the two-stage and full calibration methods provide similar effect
and variance estimates, but that the variance estimates for these two methods are slightly larger
than those from the internalized approach. As an illustrative example, we apply the methods in
a pooling project of nested case-control studies to evaluate (i) the association between circulating
vitamin D levels and risk of stroke, and (ii) how BMI modifies the association between circulating
vitamin D levels and cardiovascular disease.
Key words: Aggregation; Biomarker; Calibration; Conditional logistic regression; Pooling project; Nested
case-control study
1. Introduction
Combining data from multiple studies to maximize sample size has become a common strategy
to quantify exposure-disease associations, including those where the exposure is a biomarker. The
increased sample sizes facilitate subgroup analyses, allow more precise estimation of the biomarker
exposure effect over a wider range of biomarker measurements, and avoid issues related to data
sparsity (Key and others, 2010; Smith-Warner and others, 2006). The increase in the use of pooling
consortia over time reflects the advantages of big data in epidemiology and its promises to improve
quantification of disease risk factors. Note that we use the term pooling throughout this paper to
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refer to data combination and not physical specimen combination. Here, we define biomarkers as
measurable indicators of health at the molecular, biochemical, or cellular level (Key and others,
2010). Examples include proteins, antibodies, hormones, and blood cholesterol. Many existing pool-
ing consortia analyze biomarker-disease associations, including the Cohort Consortium Vitamin D
Pooling Project of Rarer Cancers (Gallicchio and others, 2010), the Endogenous Hormones, Nutri-
tional Biomarkers, and Prostate Cancer Collaborative Group (Key and others, 2015), the COPD
Biomarkers Qualification Consortium Database (Tabberer and others, 2017), and the Circulating
Biomarkers and Breast and Colorectal Cancer Consortium (McCullough and others, 2018), among
others.
In order to pool biomarker data, investigators must address potential between-study variation
in biomarker data due to assay or laboratory variability if not all samples are assayed at the
same laboratory with the same assay near the same time. For example, estradiol, testosterone, and
insulin-like growth factor 1 have highly variable measurements across assays (Key and others, 2010;
Tworoger and Hankinson, 2006). Measurements of blood-circulating vitamin D (25(OH)D) also
vary up to 40% between laboratories and assays (Barake and others, 2012; Lai and others, 2012;
Snellman and others, 2010). Consequently, biomarker measurements from studies conducted using
different laboratories and assays must be harmonized before pooled analyses occur if the goal is to
examine absolute concentrations using the same metric across studies. In practice, we standardize
biomarker measurements by defining study-specific calibration models. After re-assaying a random
subset of noncase biospecimens from each study at a designated reference laboratory, we estimate
study-specific models between the original “local” laboratory measurements and the reference lab-
oratory measurements. These calibration models are then used to estimate the reference laboratory
biomarker measurement among the remaining subjects in each study. Following this calibration
procedure, the standardized biomarker measurements can be used in statistical analyses. In prac-
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tice, re-assayed biospecimens are typically selected at random from controls in each study owing to
concerns about the availability of case biospecimens (Sloan and others, 2018).
Two pooling methods exist for analyzing data from multiple studies, namely the two-stage ap-
proach and aggregated approach (Smith-Warner and others, 2006; Debray and others, 2013). Under
the two-stage method, investigators complete study-specific analyses in the first stage followed by
meta-analysis in the second stage. In the second approach, investigators combine data from all par-
ticipating cohorts before performing statistical analyses on the collective dataset. Sloan and others
(2018) focused on cohort studies and subdivided the aggregated approach into the internalized and
full calibration approach. The internalized method uses the reference laboratory measurement in
the analysis when available and uses the calibrated measurement otherwise. In contrast, the full
calibration method uses calibrated biomarker measurements exclusively for all subjects regardless
of the availability of reference laboratory measurements. In this paper, we derive these approaches
under the paradigm of matched and nested case-control studies, allowing the potential inclusion of
a biomarker-covariate interaction term.
We can equivalently view pooled and calibrated biomarker data as a covariate measurement
error problem. If we treat the reference and local laboratory measurements as the true and surro-
gate biomarker values respectively (Carroll and others, 2006), we can envision each study-specific
calibration model as a different measurement error model. We leverage an existing strategy in the
measurement error literature, namely regression calibration (Carroll and others, 2006; Rosner and
others, 1990), to form the basis of our methods. Although we categorize each method as a two-stage
or aggregated approach, all methods utilize concepts underlying regression calibration.
In this paper, we propose calibration methods for pooled biomarker data from matched and
nested case-control studies that allow inference on the main effect of the biomarker in addition to
biomarker-covariate interaction terms. Section 2 presents the models and statistical methods. Sec-
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tion 3 compares the methods via simulation, stratifying by the inclusion of a covariate-biomarker
interaction term. Section 4 illustrates the methods in several examples involving 25(OH)D data
pooled from the Nurses’ Health Study I (NHS1), Nurses’ Health Study II (NHS2), and Health Pro-
fessionals Follow-up Study (HPFS) for stroke and cardiovascular disease (CVD) outcomes. Section
5 discusses our results.
2. Methods
2.1 Model and approximate conditional likelihood
Let s = 1, . . . , S index the studies contributing to the pooled analysis, where the first Q do not
use the reference laboratory to measure the biomarker of interest. For presentational simplicity, we
focus on 1 : ms matching; it is straightforward to extend the methods to settings where multiple
cases exist in some or all strata. Allow subscript i to index individuals within stratum j of study
s such that i = ms corresponds to the case and i = 0, 1, . . . ,ms − 1 correspond to the matched
controls.
Let Ysji be the binary disease outcome, Xsji be the biomarker exposure measurement from
the reference lab, Wsji be the biomarker exposure measurement from the local lab, and Zsji be a
vector of other covariates. Without further specification, all vectors are column vectors. We assume
Xsji is not available for all subjects due to the usage of a local laboratory to obtain biomarker
measurements in at least one study. However, we assume Wsji is available for all subjects in studies
obtaining measurements from local labs. Using Wsji as a direct substitute for Xsji in the analysis
will lead to biased estimates of the biomarker-outcome relationship if measurement variability exists
across the study laboratories.
To estimate the biomarker exposure effect under the aggregated approach, we develop a likelihood-
based method. The conditional logistic regression model for the biomarker-disease association is
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logit(P (Ysji = 1|Xsji,Zsji)) = β0sj + βxXsji + βTz Zsji, (2.1)
where β0sj is a stratum-specific intercept and βz is a vector of covariate effects. We aim to provide
point and interval estimates for βx. For nested case-control studies using incidence density sampling,
βx is the log relative risk (RR) describing the biomarker-disease association (Prentice and Breslow,
1978).
Let vectorsXsj ,Wsj , and matrix Zsj contain their respective measurements from all individuals
in stratum j of study s. The conditional likelihood (Breslow and others, 1978) is
L =
∏
s
∏
j
P (Ysj0 = 0, . . . , Ysj(ms−1) = 0, Ysjms = 1|Xsj ,Zsj ,
ms∑
i=0
Ysji = 1)
=
∏
s
∏
j
exp{β0sj + βxXsjms + βTz Zsjms}∑ms
i=0 exp{β0sj + βxXsji + βTz Zsji}
=
∏
s
∏
j
(
1 +
ms−1∑
i=0
exp{βx(Xsji −Xsjms) + βTz (Zsji −Zsjms)}
)−1
.
The conditional likelihood contribution cannot be computed for studies using a local laboratory
because Xsji is unavailable for individuals outside the calibration subset. Under a surrogacy as-
sumption, we derive an approximate conditional likelihood below that uses an estimate of Xsji
in place of Xsji itself. This surrogacy assumption states that f(Ysji|Xsji,Zsi,Wsi,
∑ms
i=1 Ysji =
1) = f(Ysji|Xsji,Zsji,
∑ms
i=1 Ysji = 1); in essence, the reference laboratory measurement provides
at least as much information about the likelihood of disease as the local laboratory measurement,
conditional on the covariates and matching scheme.
Under aggregation, the likelihood contribution from a stratum with only local laboratory biomarker
measurements is
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lsj = P (Ysj0 = 0, . . . , Ysjms = 1|Wsj ,Zsj ,
ms∑
i=0
Ysji = 1)
=
∫
P (Ysj0 = 0., . . . , Ysjms = 1|Xsj ,Wsj ,Zsj ,
ms∑
i=0
Ysji = 1)f(Xsj |Wsj ,Zsj ,
ms∑
i=0
Ysji = 1)dXsj
=
∫ (
1 +
ms−1∑
i=0
exp{βx(Xsji −Xsjms) + βTz (Zsji −Zsjms)}
)−1
f(Xsj |Wsj ,Zsj ,
ms∑
i=0
Ysji = 1)dXsj
= EXsj |Wsj ,Zsj ,
∑ms
i=0 Ysji=1
[
(1 +
∑ms−1
i=0
exp{βx(Xsji −Xsjms) + βTz (Zsji −Zsjms)})−1
]
,
where the surrogacy assumption is used in the third line. A second order Taylor series approximation
about Xsj with respect to E[Xsj |Wsj ,Zsj ,
∑ms
i=0 Ysji = 1] yields the approximate contribution by
stratum j of study s, namely
l˜sj =
(
1 +
ms−1∑
i=0
exp{βx(X˜sji − X˜sjms) + βTz (Zsji −Zsjms)}
)−1
,
where X˜sji − X˜sjms = E[Xsji|Wsji,Zsji,
∑ms
i=0 Ysji = 1] − E[Xsjms |Wsjms ,Zsjms ,
∑ms
i=0 Ysji = 1].
This approximate conditional likelihood performs best when the elements in the variance-covariance
matrix V ar(Xsj |Wsj ,Zsj ,
∑ms
i=0 Ysji = 1) are small (i.e. there is minimal noise in the relationship
between Xsji and Wsji conditional on the covariates and matching scheme) or when the association
between Ysji and Xsji is not strong. Further details about these conditions and the full derivation
of the approximate conditional likelihood are available in Section 1 of the Supplementary Mate-
rials. The presence of E[Xsji|Wsji,Zsji,
∑ms
i=0 Ysji = 1] in the approximate conditional likelihood
contribution l˜sj motivates the construction of calibration models.
2.2 Calibration model
We formulate study-specific calibration models among studies using a local laboratory to evaluate
l˜sj above under the aggregated approaches. In each study using a local lab, we estimate a calibration
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model from a subset of controls who have both reference and local laboratory measurements avail-
able. The resulting model quantifies the relationship between Xsji and Wsji and is used to estimate
the reference laboratory measurement among individuals with only a local laboratory measurement.
For presentational simplicity, we drop Zsji from the calibration models such that
E[Xsji|Wsji,Zsji,
∑ms
i=0 Ysji = 1] ≈ E[Xsji|Wsji,
∑ms
i=0 Ysji = 1]. Previous work demonstrates that,
when not conditional on
∑ms
i=0 Ysji = 1, omitting Zsji has a negligibly small impact on the resulting
calibration models so long as Zsji is not very strongly correlated with Xsji (Sloan and others, 2018).
The additional condition,
∑ms
i=0 Ysji = 1, does not change this conclusion.
We assume a linear relationship between the reference and local laboratory measurements among
the matched cases and controls such that
E[Xsji|Wsji,
ms∑
i=0
Ysji = 1] = as + bsWsji, (2.2)
where as and bs are the calibration parameters. Note that model (2.2) indicates that the calibra-
tion parameters are study-specific and invariant over the strata of each study. The assumption of
invariance over strata could be relaxed by instead assuming E[Xsji|Wsji,Usji,
∑ms
i=0 Ysji = 1] =
as + bsWsji + c
T
s Usji, where Usji is a vector that may contain some or all of the matching factors.
Previous work suggests that the simple linear model in (2.2) is appropriate and sufficient in most
settings (Sloan and others, 2018; Gail and others, 2016).
Due to concerns about the availability of case biospecimens for re-assay at the reference labo-
ratory, the calibration models in (2.2) are typically fit among controls only, i.e. Eˆ[Xsji|Wsji, Ysji =
0] = aˆs,co + bˆs,coWsji. While aˆs,co and bˆs,co are generally not consistent estimators of as and bs, we
can show that the controls-only parameters approximate the parameters of model (2.2) under some
relatively mild conditions. Specifically, under multivariate normality of (Xsj ,Wsj), aˆs,co converges
to a value close to as when E[Xsj |
∑ms
i=0 Ysji = 1] ≈ E[Xsj |Ysj = 0] and V ar(Xsj |
∑ms
i=0 Ysji =
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1) ≈ V ar(Xsj |Ysj = 0), and bˆs,co converges to a value close to bs when V ar(Xsj |
∑ms
i=0 Ysji =
1) ≈ V ar(Xsj |Ysj = 0). In addition, if the biomarker effect is small (that is, βx ≈ 0), then aˆs,co
and bˆs,co also converge to values close to as and bs. Further mathematical details are available in
Section 2 of the Supplementary Materials. We also illustrate the approximation for a single study
via simulation, using simulation parameters listed in section 3.1. Over 1000 simulation replicates,
the mean percent bias of the estimated parameters in (2.2) is close to zero while the controls-only
calibration parameter estimates are only depressed up to twelve percent for very large RRs (Figure
1). The intercept estimates are typically more biased than the slope estimates, and the downward
bias is more pronounced for increasingly non-null RRs. Simulations for other values of as and bs (not
shown here) demonstrate that these patterns are invariant to the specific values of the calibration
parameters.
Let X˜sji be the estimated biomarker measurement used in place of Xsji in the aggregated
analysis. Its value depends on the chosen calibration approach and availability of the reference
laboratory measurement. For studies using the reference laboratory for all biomarker measurements,
no calibration occurs and X˜sji = Xsji for all study participants. For studies using a local lab, the
full calibration and internalized methods are defined as follows:
Full calibration method: X˜sji = Eˆ[Xsji|Wsji, Ysji = 0]
Internalized method: X˜sji =
{
Xsji, if reference laboratory measurement available
Eˆ[Xsji|Wsji, Ysji = 0], otherwise,
where Eˆ[Xsji|Wsji, Ysji = 0] = aˆs,co+ bˆs,coWsji. The pooled analysis uniformly applies one of these
methods to all studies using local laboratories.
The biomarker measurements appear in the likelihood via the difference Xsji −Xsjm. For the
full calibration method, the calibrated difference simplifies to X˜sji− X˜sjm = bˆs,co(Wsji−Wsjm) for
all observations. Consequently, bias in the intercept aˆs,co does not impact the βx estimator under
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the full calibration method. In contrast, for observations in the calibration study subset under the
internalized method, X˜sji− X˜sjm = Xsji− (aˆs,co + bˆs,coWsji). Thus, bias in both the intercept and
slope estimates aˆs,co and bˆs,co induces bias in the internalized method βx estimate. We will see in
simulation studies that the relative performance of the internalized, full calibration, and two-stage
methods is impacted by the size of the calibration subset.
2.3 Parameter estimation
Define β = [βx,βz], a = [a1, . . . , aQ], and b = [b1, . . . , bQ] such that our target of estimation is
θ = [a, b,β]. We define estimating equations [ψa,ψb, ψβx ,ψβz ] = 0, where ψa, ψb, ψβx , and ψβz
are approximately unbiased estimating functions for their respective parameters (see Section 3 of
the Supplementary Materials).
Estimates of β are obtained through a two step process involving the pseudo maximum likelihood
estimation method (Gong and Samaniego, 1981). We first estimate the calibration parameters aˆ
and bˆ by fitting the linear regression calibration models. We then obtain βˆ using pseudo-maximum
conditional likelihood estimation over the set of estimating equations [ψβx(aˆ, bˆ),ψβz (aˆ, bˆ))] = 0,
where instances of a and b have been replaced with their estimates. Since the estimating equations
for β are with respect to l˜sj where aˆ and bˆ are treated as known, the estimates are not the same
as those obtained from maximizing a joint likelihood, which is the product of the likelihood for β
and the likelihood for a and b.
We must account for uncertainty in the estimation of aˆ and bˆ when estimating V̂ ar(βˆ). As
a result, we use the sandwich variance formulas over the entire set of estimating equations. The
appropriate diagonal terms of the sandwich variance matrix provide variance estimates for βˆ (see
Section 4 of the Supplementary Materials).
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2.4 Two-stage approach
The two-stage approach for pooled data uses regression calibration, a broadly applicable method
initially developed in the measurement error literature, to adjust for calibration in the first stage
study-specific analyses (Carroll and others, 2006; Rosner and others, 1990; Spiegelman and others,
1997, 2001). The second stage combines these estimates using fixed effects meta-analysis.
Regression calibration for cohort studies using standard logistic regression has been robustly
developed by Rosner, Spiegelman, and Willett, among others (Rosner and others, 1989, 1990; Carroll
and others, 2006). However, there has been less focus on the application of regression calibration
to the setting of matched data with conditional logistic regression. Using simulation studies and
randomly sampled internal validation studies, McShane and others (2001) tested the performance
of the regression calibration point estimate formula to obtain βx point estimates under conditional
logistic regression. Their results demonstrated that regression calibration performed comparably
to other measurement error methods for exposure effects that were not too strong. Effectively, the
matched nature of the data is ignored in the calibration step but accounted for in the regression
step. Further simulations by Guolo and Brazzale (2008) established the ready extension of regression
calibration to the matched data setting. However, neither manuscript provided simulations specific
to the setting of controls-only calibration data, which we consider analytically in Supplementary
Materials Section 2 and via simulation in Section 3.
The assumptions required by regression calibration for matched case-control studies are similar,
including: (i) the surrogacy assumption defined in section 2.1, and (ii) the noise in the calibration
model is moderate and/or the association between Y and X is not too strong.
We briefly describe the two-stage method and its implementation of regression calibration.
For studies using the reference lab for all biomarker measurements, we directly obtain effect and
variance estimates from a conditional logistic regression model. Among studies whose biomarkers
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were measured by local lab, we estimate βˆx,q, the adjusted effect estimate in study q obtained from
the regression calibration method such that
βˆx,q = βˆw,q/bˆq,
V̂ ar(βˆx,q) = bˆ
−2
q V̂ ar(βˆw,q) + bˆ
−4
q βˆ
2
w,qV̂ ar(bˆq),
(2.3)
where bˆq is obtained from the calibration study and βˆw,q and V̂ ar(βˆw,q) are the naive estimates from
a conditional logistic regression model fit using all local laboratory measurements of the individuals
in study q. Formula (2.3) for V̂ ar(βˆx,q) leverages the fact that the conditional logistic regression
estimates, βˆw,q, and the calibration parameter estimate, bˆq are uncorrelated asymptotically (proof
in Section 5 of Supplementary Materials). Fixed-effects meta-analysis then combines the study-
specific estimates using inverse variance weights to obtain a final effect and variance estimate for
βˆx.
2.5 Two-stage method for models with an interaction term
Suppose Vsji is a covariate whose interaction with Xsji is of interest. The conditional logistic
regression model with an interaction term between Xsji and Vsji is
logit(P (Ysji = 1|Xsji, Vsji,Zsji)) = β0sj + βxXsji + βvVsji + βxvXsjiVsji + βTz Zsji. (2.4)
For the aggregated methods, the development of an approximate conditional likelihood involving
an interaction term follows similarly to section 2.1 (see Section 1 of the Supplementary Materials).
However, the two-stage method for models involving interaction terms must be modified to address
inference for (βx, βv, βxv). In q
th study using a local laboratory, suppose we fit the following naive
model using all local laboratory biomarker measurements:
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logit(P (Yqji = 1|Wqji, Vqji,Zqji)) = β∗0qj + β∗w,qWqji + β∗v,qVqji + β∗wv,qWqjiVqji + βT∗z,qZqji.
Like before, assume we obtain study-specific estimates aˆq and bˆq by fitting the linear model
E[Xqji|Wqji, Yqji = 0] = aˆq + bˆqWqji in each calibration subset. We derive a modified form of
regression calibration to obtain adjusted point estimates of βx, βv, and βxv in each study using a
local laboratory such that
βˆx,q =
βˆ∗w,q
bˆq
, βˆv,q = βˆ
∗
v,q −
aˆqβˆ
∗
wv,q
bˆq
, βˆxv,q =
βˆ∗wv,q
bˆq
.
The full derivation of the point and variance estimates can be found in Supplement Section 6.
Of note, the formulas for the point and variance estimates of βˆx,q follow similarly to the case of
no interaction term. The estimates for βˆxv,q follow similarly to βˆx,q, and βˆv,q has a slightly more
complex adjustment given the interaction term between Xsji and Vsji.
3. Simulations
3.1 Model without an interaction term
We simulated 1:1 matched case-control data by generating data for each stratum and then selecting
a case and control at random from each stratum. Let esji be the error term in the linear regression
of Xsji on Wsji. We assumed joint multivariate normality of (Xsji,Wsji, esji) and generated data
such that
XsjiWsji
esji
 ∼ MVN
 µx(µx − as)/bs
0
 ,
σ2x bsσ2ws σ2x − b2sσ2ws· σ2ws 0
· · σ2x − b2sσ2ws
 .
This formulation induces E[Xsji|Wsji] = as + bsWsi and Cov(Wsji, esji) = 0. We supposed that
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the stratum-specific intercepts β0sj were normally distributed such that β0sj ∼ N(µβ0 , σ2β0), and
used a simple risk model without covariates, logit(P (Ysji = 1|Xsji)) = β0sj + βxXsji.
We set µx = 0, σ
2
x = 1, µβ0 = −1 and σ2β0=0.01. We assumed four studies contributed to the final
analysis, each with 1000 total subjects (or 500 case-control pairs) and 100 calibration participants,
and assigned calibration parameters a = [−3, 1,−1, 3], and b = [0.5, 0.75, 1.25, 1.5]. We completed
1000 simulation replicates at six RRs, including (1.25, 1.5, 1.75, 2, 2.25, 2.5).
We compared the two aggregated procedures and the two-stage approach with regard to mean
percent bias over the simulation replicates, mean squared error (MSE), and coverage rate, defined
as the proportion of simulation replicates whose 95% confidence intervals covered the true βx. For
comparison, we also included a naive method that does not calibrate and uses Wsji in the logistic
regression. We assumed that increasing levels of the biomarker increased disease risk, although
similar results were obtained when the biomarker was instead protective against disease. We provide
tables of results in the main paper and include graphs of the mean percent bias estimates from these
tables in Section 7 of the Supplementary Materials.
As shown in Table 1, the naive method performed poorly over all effects and underscored the
need for calibration. At every RR considered, the percent bias of the naive estimate exceeded -27%
and the corresponding coverage rates were less than 40%. The full calibration method estimates were
consistently less biased than the internalized method estimates. Over the range of RRs considered,
the internalized estimate was biased downward by approximately three to four percent while the
full calibration estimate was biased by less than one percent. For large RRs greater than or equal
to 2.0, the coverage rate under the internalized method was 90% to 91% due to depression of point
estimates. In contrast, the coverage rates of the full calibration and two-stage methods ranged from
93% to 96%. The two-stage approach generally performed comparably to the full calibration method
with regards to percent bias in the RR estimate, MSE, and coverage rate.
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We also performed simulations that fixed the total sample size at 1000 participants while varying
the calibration subset size between 30, 50, and 150 subjects (or 3%, 5%, and 15% participation rates,
respectively). As shown in Figure 2, at all calibration study sizes, the full calibration method offered
nearly unbiased point estimates. However, the internalized method estimates experienced increasing
downward bias as the proportion of subjects participating in the calibration subset increased owing
to increasingly differential calibration of cases and controls. As calibration study size increased, the
two-stage method point estimates were increasingly less biased owing to the improved estimation
of calibration parameters.
3.2 Model with an interaction term
For the simulations involving a model with an interaction term, we also generated Vsji in the
multivariate normal model for each stratum such that
WsjiVsji
esji
 ∼ MVN
µwsµv
0
 ,
σ2ws σwvs 0· σ2v 0
· · σ2e
 ,
Xsji = as + bsWsji + esji,
where µws = (µx − as)/bs, σwvs = Cov(Wsji, Vsji), and σ2ws = (σ2x − σ2e)/b2s. We again used 1:1
matching and omitted other covariates such that the risk model was logit(P (Ysi = 1|Xsji, Vsji)) =
β0sj + βxXsji + βvVsji + βxvXsjiVsji. Like before, we assumed four studies contributed to the
analysis, each with 1000 total subjects and 100 individuals in the calibration subset. We set µx =
µv = 0, σ
2
x = σ
2
v = 1, a = (−3, 1,−1, 3), b = (0.5, 0.75, 1.25, 1.5), and Corr(Xsji, Vsji) = 0.2,
which in turn induced σwvs for each study. We considered the same range of RRs for the main
effect of the biomarker measurement and also chose four combinations of (βv, βxv) to address all
possible qualitative effects of the covariate and interaction term, including (exp(βv), exp(βxv)) ∈
[(0.8, 0.8), (0.8, 1.2), (1.2, 0.8), (1.2, 1.2)]. The simulation results for (exp(βv), exp(βxv)) = (1.2, 1.2)
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are reported in Table 2 while the results for (exp(βv), exp(βxv)) ∈ [(0.8, 1.2), (1.2, 0.8), (1.2, 1.2)] are
presented in Section 7 of the Supplementary Material.
We focus first on the operating characteristics of βˆx (Table 2, and Table 1 and Figure 2 of
Section 7 of the Supplementary Materials). The mean βˆx estimate under the internalized method
is consistently biased downward by two to four percent across all effect sizes and all combinations
of (exp(βv), exp(βxv)). The full calibration and two-stage point estimates were separated by no
more than one percent and were approximately unbiased for the true RR. All methods performed
markedly better than the naive approach, whose point biases ranged from -32 to -23 percent. The
MSE of the two-stage and aggregated methods were similar across all effect combinations.
For βv, the full calibration and two-stage approach also performed similarly with regard to
percent bias (Table 2, and Table 2 and Figure 2 of Section 7 of the Supplementary Materials). The
internalized method estimate was the least biased near the null of βx but became more biased for
increasingly protective or deleterious effects. For example, when (βx, βv, βxv) = (1.2, 1.2, 1.2), the
percent bias of βv was 1.5%, and when (βx, βv, βxv) = (2.5, 1.2, 1.2), the percent bias of βv was
7.6%. The naive estimates of βv were increasingly biased as |βx| increased, with biases reaching
-28.3 and 23.0 percent in some settings.
Across all combinations of effects, the percent bias in estimates of βxv from all three calibration
methods were contained within (-4.9%, 3.9%) (Table 2, and Table 3 and Figure 2 of Section 7 of
Supplementary Materials). The βˆxv estimate under the internalized method was frequently more
biased than the corresponding estimates under the full calibration or two-stage approaches, which
performed similarly to each other. The naive method performed poorly and the percent bias in its
βxv estimates ranged from -105.4% to -81.7%.
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4. Applied example
We completed two data examples to illustrate the methods. In the first example, we investigate
the impact of circulating 25-hydroxyvitamin D (25(OH)D) levels on risk of stroke. In the second
example, we investigate the impact of 25(OH)D levels and its interaction with a dichotomized
BMI term on the risk of a composite outcome, fatal or nonfatal stroke or myocardial infarction
(henceforth referred to as the CVD endpoint). In both examples, we match each case to a single
control based on sex and age at blood draw.
We applied the aggregated, two-stage, and naive methods to combine data derived from three
large prospective cohort studies in the United States, including the HPFS (Wu and others, 2011),
the NHS1 (Eliassen and others, 2016), and the NHS2 (Eliassen and others, 2011). The HPFS began
enrollment in 1986 and includes 51,529 male health professionals aged 40 to 75 years at baseline. The
NHS1 enrolled 121,701 female nurses aged 30 to 55 years at baseline in 1976. The NHS2, a younger
counterpart to the NHS1, was established in 1989 with the enrollment of 116,671 female nurses, aged
25 to 42 years at baseline. In each cohort, participants completed biannual questionnaires providing
information about medical history, diet, and lifestyle conditions; further general discussion of each
cohort is available elsewhere (Grobbee and others, 1990; Colditz and others, 1997; Rich-Edwards
and others, 2002). Between 1989 and 1997, each study completed laboratory assays on blood samples
for a host of biomarkers, including 25(OH)D, from a subset of participants (Wu and others, 2011;
Eliassen and others, 2016, 2011). Subjects with a previous cancer diagnosis were not eligible for
random selection. Individuals were excluded from the pooled analysis if they did not have 25(OH)D
measurements available or stroke or myocardial infarction outcome data.
Each study obtained calibration data among a subset of controls by re-assaying their blood
samples at Heartland Assays, LLC (Ames, IA) during 2011-2013. Circulating 25(OH)D levels were
standardized to 20 nmol/L increments. Information about the main studies and the calibration
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subsets, including the parameter estimates of the study-specific calibration models, is presented in
Table 3.
In the first example involving the stroke endpoint, we pooled 179 matched case-control pairs.
Previous work by Sun and others (2012) showed that individuals with 25(OH)D measurements in the
top tertile of the population had reduced risk of stroke compared to individuals with measurements
in the bottom tertile. Our analyses coarsely matched on age (grouped into tertiles in each cohort)
and adjusted for years of follow-up after blood draw, smoking status (never/ever), family history of
myocardial infarction (yes/no), personal history of hypertension (yes/no), BMI (less than or greater
or equal to 25 kg/m2), and personal history of diabetes (yes/no). The internalized, full calibration,
and two-stage methods all demonstrate that increased 25(OH)D levels correlate with a small, non-
significant protective effect against stroke, with RRs of 0.95, 0.96, and 0.95 respectively (Table 6).
The naive approach, which pools all local laboratory measurements directly without adjustment,
yielded a RR of 0.99 and a confidence interval that was narrower than those estimated under the
calibration methods.
In the second example involving the CVD endpoint, we pooled 624 case-control pairs. Some
literature suggests that vitamin D deficiency is more deleterious among individuals with high BMI
(Weng and others, 2013; Levi-Vardi and Yagil, 2017). We dichotomized BMI into a binary variable
with value 1 if the subject is not overweight (BMI<25 kg/m2) and value 0 otherwise. In addition
to the matching factors, analyses were adjusted for years of follow-up after blood draw, smoking
status (never/ever), family history of myocardial infarction (yes/no), personal history of hyperten-
sion (yes/no), and personal history of diabetes (yes/no). The estimated regression coefficients and
confidence intervals for 25(OH)D, BMI, and their interaction are presented in Table 5. All pooling
methods indicated that having higher circulating 25(OH)D and a non-overweight BMI were asso-
ciated with a lower risk of stroke. Based on the results in Table 5, the RR from the aggregated and
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two-stage methods associated with a 20 nmol/L increase in 25(OH)D among subjects with a BMI
less than 25 kg/m2 ranged from 0.85 to 0.86, while the RR from the naive analysis was 0.78. Among
overweight subjects, the corresponding RR from the calibration methods ranged from 0.91 to 0.92,
and the naive RR estimate was 0.84 (see Table 4 of Section 7 in the Supplementary Materials). As
this illustrative example demonstrates, the bias in the naive RR estimate for models including inter-
action term is not necessarily towards the null. The bias may be toward the alternative hypotheses
and thus lead to false-positive scientific findings.
5. Discussion
In this work, we proposed statistical methods for calibrated biomarker data pooled across multiple
nested case-control studies. Our methods facilitate inference on the main effect of the biomarker
as well as a biomarker-covariate interaction term. Keeping with common practice, we estimated
study-specific calibration models from subsets of controls re-assayed at the reference lab.
Several recommendations and observations stem from our work. Regardless of whether one is
interested in the main effect of the biomarker or the interaction term, the full calibration approach is
the preferred aggregated method for calibrating biomarker measurements that were measured using
different laboratories and/or assays. Average percent bias in βx and βxv estimates are minimized
by the full calibration method. Due to using a controls-only calibration scheme, we observed that
(aˆs,co, bˆs,co) were slightly biased for the parameters in model (2.2) for strong biomarker effects. Any
bias in these estimates is uniformly incorporated in both cases and controls under the full calibration
approach such that bias is minimized in the βx and βxv estimates. In fact, the intercept aˆs,co cancels
out in the approximate conditional likelihood contribution for the full calibration approach, which
does not occur for the internalized method.
Under the two-stage method, we also derived estimators with analytic variances for conditional
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logistic regression models including an interaction term between the biomarker exposure and a
potential effect modifier. We consistently observed that the full calibration and two-stage methods
offered similar point estimates, standard errors, and coverage rates. In simulation, the difference
in effect estimates between the full calibration and two-stage methods was less than two percent
regardless of the inclusion of an interaction term. When incorporating an interaction term, the
direction of bias in βv was not consistent and depended on the direction and magnitude of βx and
βv. Naive estimates were typically quite biased and illustrated the risk of failing to implement a
calibration step when necessary. More problematically, the naive estimates were sometimes biased
toward the alternative, resulting in an inflated type I error rate.
Although the aggregated and two-stage methods are equally viable and valid options for ana-
lyzing pooled data, logistical considerations may dictate the preferred approach for the statistical
analysis. For instance, aggregated methods often lend themselves better to subgroup analyses be-
cause they reduce issues resulting from data sparsity. If the main exposure effect and at least some
covariate effects are homogeneous, the aggregated method may also offer efficiency gains in co-
variate estimation relative to the two-stage method (Lin and Zeng, 2010). However, the two-stage
method may be more appealing than the aggregated methods at times for its intuitive and simple
implementation, and its robustness to these covariate homogeneity assumptions.
6. Software
Functions in the form of R code is available at the first author’s Github account and
https://www.hsph.harvard.edu/molin-wang/software.
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7. Supplementary Material
Supplementary material is available online at http://biostatistics.oxfordjournals.org. Sec-
tion 1 derives the approximate likelihood; Section 2 discusses the calibration parameters under
controls-only calibration; Sections 3 and 4 give the estimating equations and sandwich variance
estimator respectively; Section 5 demonstrates zero covariance between the naive estimate from
conditional logistic regression and calibration parameter estimates; Section 6 derives formulas for
the two-stage method with an interaction term; Section 7 gives additional figures and tables.
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Fig. 1. Comparison of percent bias in average calibration parameter estimates over 1000 simulation replicates
for a single study’s calibration parameters when fitting the model E[Xsji|Wsji,∑msi=0 Ysji = 1] = aˆs+bˆsWsji,
where (as, bs) = (3, 0.8) in the data generating mechanism. The model parameters in (2.2) result from
fitting a calibration model in the cases and controls of the nested case-control study, while the controls-only
parameters result from fitting a calibration model among only controls.
Fig. 2. Comparison of methods as number of participants in the calibration study increases. The number of
subjects in each study remains fixed at 1000, or equivalently, 500 case-control pairs. The calibration study
participation rates considered are 3%, 5%, and 15%, or 30, 50, and 150 individuals respectively.
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Table 3. Number of case-control pairs (N), size of the calibration study (ncal), and the estimated intercept
(aˆ) and slope (bˆ) of the calibration model for each study participating in the pooled analysis.
Model 1: Stroke endpoint Model 2: CVD endpoint
Study N ncal aˆ (SE) bˆ (SE) N ncal aˆ (SE) bˆ (SE)
HPFS 49 25 4.35 (2.80) 0.94 (0.04) 406 18 5.33 (3.72) 0.93 (0.05)
NHS1 103 27 6.50 (2.88) 0.84 (0.04) 175 27 6.50 (2.88) 0.84 (0.04)
NHS2 27 28 9.01 (4.88) 0.95 (0.07) 43 28 9.01 (4.88) 0.95 (0.07)
Total 179 80 624 73
Table 4. Point and RR estimates for the association of circulating 25(OH)D* and stroke, adjusting for years
of follow-up after blood draw, BMI (overweight or not), smoking (never/ever), family history of myocardial
infarction (yes/no), hypertension (yes/no), and diabetes (yes/no).
Method βˆx RR RR 95% CI
Internalized -0.051 0.950 (0.721, 1.253)
Full calibration -0.046 0.955 (0.715, 1.276)
Two-stage -0.048 0.953 (0.717, 1.266)
Naive -0.018 0.983 (0.833, 1.159)
*Estimates correspond to a 20 nmol/L increase in circulating 25(OH)D
Table 5. Point estimates with 95% confidence intervals for circulating 25(OH)D, BMI*, and their interaction
with CVD as the outcome event, adjusting for years of follow-up after blood draw, smoking (never/ever),
family history of myocardial infarction (yes/no), hypertension (yes/no), and diabetes (yes/no).
Method 25(OH)D BMI BMI × 25(OH)D
Internalized -0.091 (-0.232, 0.050) -0.592 (-0.663, -0.521) -0.072 (-0.267, 0.123)
Full calibration -0.089 (-0.246, 0.068) -0.587 (-0.661, -0.513) -0.069 (-0.271, 0.133)
Two-stage -0.086 (-0.244, 0.072) -0.569 (-0.643, -0.495) -0.066 (-0.266, 0.135)
Naive -0.173 (-0.380, 0.032) -0.163 (-0.374, 0.053) -0.082 (-0.180, 0.016)
*BMI is treated as a dichotomized variable taking value 1 if less than 25kg/m2 and 0 otherwise
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